Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease

21 września 2026 zaktualizowane przez: Jing He, Peking University People's Hospital

A Prospective Cohort Study of Telitacicept Versus Conventional Immunosuppressive Agents in Primary Sjögren's Disease With Interstitial Lung Disease

This study aims to evaluate the efficacy Telitacicept in patients with primary Sjögren's Disease with interstitial lung disease

Przegląd badań

Status

Rekrutacyjny

Warunki

Interwencja / Leczenie

Szczegółowy opis

This is a prospective, open-label, single-center cohort study to evaluate the real-world effectiveness of Telitacicept compared with conventional immunosuppressive therapy in patients with primary Sjögren's disease associated interstitial lung disease. A total of 60 patients with confirmed interstitial lung disease by high-resolution computed tomography will be enrolled and allocated into two cohorts based on the treatment regimen selected by their treating physician according to clinical indications and patient preference: one cohort receiving Telitacicept 160 mg subcutaneously once weekly and the other receiving conventional immunosuppressive agents.

Treatment effectiveness will be evaluated over 24 weeks. The primary outcome is the change from baseline in forced vital capacity percent predicted (FVC% predicted) at Week 24. Secondary assessments include DLCO% predicted, total lung capacity, HRCT changes quantified using the Warrick score, KL-6, ESSDAI. Changes in B-cell subsets and related biomarkers will be explored for associations with pulmonary outcomes.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

60

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

      • Beijing, Chiny
        • Rekrutacyjny
        • Department of Rheumatology and Immunology, Peking University People's Hospital
        • Kontakt:
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 70 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

The study population will consist of 60 adult patients with primary Sjögren's disease and HRCT-confirmed interstitial lung disease, enrolled and allocated to treatment groups based on real-world clinical practice.

Opis

Inclusion Criteria:

  1. Age 18 to 70 years, male or female.
  2. Diagnosis of primary Sjögren's Syndrome meeting the 2016 ACR/EULAR classification criteria.
  3. Confirmed diagnosis of Interstitial Lung Disease by High-Resolution Computed Tomography (HRCT).
  4. Stable doses of corticosteroids and immunosuppressants (e.g., mycophenolate mofetil) for at least 1 week prior to enrollment.
  5. Willing and able to provide written informed consent

Exclusion Criteria:

  1. Allergy: Known allergy or hypersensitivity to Telitacicept or any of its excipients.

  2. Concomitant Autoimmune Diseases: Diagnosis of other systemic autoimmune diseases besides Sjögren's Syndrome, such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Mixed Connective Tissue Disease (MCTD), or ANCA-associated vasculitis. (Note: Secondary Sjögren's Syndrome is not excluded on this basis alone, but the primary condition must be considered).

  3. Laboratory Abnormalities (at Screening):

    Hematology:

    Hemoglobin (Hb) < 85 g/L. White Blood Cell count (WBC) < 3.0 × 10^9/L. Neutrophil count (NEUT) < 1.5 × 10^9/L. Platelet count (PLT) < 80 × 10^9/L.

    Liver Function:

    Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) > 2.5 × the upper limit of normal (ULN).

    Total bilirubin (TBIL) > 1.5 × ULN.

    Kidney Function:

    Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m². Or serum creatinine (Cr) > 1.5 × ULN.

  4. Significant Organ Diseases or Comorbidities:

    Cardiovascular: Myocardial infarction or unstable angina within the past 6 months; uncontrolled hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg); pulmonary arterial hypertension with evidence of right heart failure.

    Respiratory: Presence of other significant lung diseases (e.g., COPD, asthma, pulmonary embolism, active pulmonary tuberculosis).

    Gastrointestinal: Active peptic ulcer, gastrointestinal bleeding, or pancreatitis.

    Malignancy: History of any malignancy within the past 5 years (excluding successfully treated basal cell carcinoma of the skin or in-situ cervical carcinoma).

    Psychiatric: Severe mental illness (e.g., severe depression, schizophrenia) or cognitive impairment that may interfere with compliance.

  5. Prior/Concomitant Medications:

    Use of rituximab, belimumab, TNF inhibitors (e.g., etanercept, adalimumab), or ther biologic agents (e.g., IL-6, IL-17, IL-23 inhibitors) within 3 months prior to screening.

    Participation in another interventional clinical trial (receiving investigational drug or device) within 4 weeks prior to screening.

  6. Active Infection:

    Presence of an active infection requiring systemic anti-infective treatment at screening.

    Active tuberculosis (positive T-SPOT.TB or TST with chest X-ray/CT findings suggestive of active disease).

    Positive HIV antibody. Positive Hepatitis B surface antigen (HBsAg), or positive Hepatitis B core antibody (HBcAb) with detectable HBV DNA.

    Positive Hepatitis C antibody with detectable HCV RNA.

  7. Special Populations:

    Women who are pregnant or breastfeeding. Women of childbearing potential who are unwilling or unable to use highly effective contraceptive methods from screening until at least 3 months after the last dose of study drug.

    Patients planning to undergo major surgery during the study period.

  8. Other Situations:

Inability to cooperate with pulmonary function tests (e.g., due to severe cognitive impairment or dyspnea).

Any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in this study (e.g., poor compliance, inability to understand study procedures).

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: COHORT
  • Perspektywy czasowe: PROSPECTIVE

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
The telitacicept group

Patients in the treatment group will receive subcutaneous telitacicept 160 mg once weekly for 24 weeks, in addition to their background therapy (hydroxychloroquine and/or conventional immunosuppressive agents), and will be followed up regularly.

The study duration was 24 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 24 weeks.

Conventional treatment with methylprednisolone (≤ 40 mg/day) and other immunosuppressive agents (including but not limited to cyclophosphamide, tacrolimus, sirolimus, cyclosporine, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine, tripterygium glycosides, methotrexate, and sulfasalazine).

Treatment restrictions: The use of immunosuppressants was limited to a maximum of three agents throughout the 24-week period, and dose adjustments from baseline were restricted to within 30%.

The control group

Participants in the control group will receive background therapy (hydroxychloroquine and/or conventional immunosuppressive agents) alone for 24 weeks, and will be followed up regularly according to the same schedule.

Conventional treatment with methylprednisolone (≤ 40 mg/day) and other immunosuppressive agents (including but not limited to cyclophosphamide, tacrolimus, sirolimus, cyclosporine, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine, tripterygium glycosides, methotrexate, and sulfasalazine).

Treatment restrictions: The use of immunosuppressants was limited to a maximum of three agents throughout the 24-week period, and dose adjustments from baseline were restricted to within 30%.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change From Baseline in Forced Vital Capacity Percent Predicted at Week 24
Ramy czasowe: At baseline and at week 12,24

FVC will be measured using standardized pulmonary function testing and expressed as the percentage of the predicted value. The outcome will be calculated as Week 24 FVC% predicted minus baseline FVC% predicted. The adjusted between-group difference will be estimated between the telitacicept and conventional-treatment cohorts.

At baseline and at week 12,24

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change From Baseline in Diffusing Capacity for Carbon Monoxide Percent Predicted at Week 24
Ramy czasowe: Baseline, Week 12, and Week 24

The outcome will be calculated as Week 24 DLCO% predicted minus baseline DLCO% predicted.

Baseline, Week 12, and Week 24
Change From Baseline in Total Lung Capacity at Week 24
Ramy czasowe: Baseline, Week 12, and Week 24

Total lung capacity will be measured by standardized pulmonary function testing. Both the observed value and percent predicted, where available, will be recorded.

Baseline, Week 12, and Week 24
Change From Baseline in HRCT Warrick Score at Week 24
Ramy czasowe: Baseline and Week 24

HRCT abnormalities will be assessed using the Warrick scoring system. The severity score ranges from 0 to 15 and is based on five abnormalities: ground-glass opacity (1 point), irregular pleural margins (2 points), septal or subpleural lines (3 points), honeycombing (4 points), and subpleural cysts (5 points). For each abnormality, extent is scored according to the number of bronchopulmonary segments involved: 1-3 segments (1 point), 4-9 segments (2 points), and more than 9 segments (3 points), giving a total extent score of 0-15. The Warrick total score is the sum of severity and extent scores and ranges from 0 to 30, with higher scores indicating greater ILD involvement.

Baseline and Week 24
Change From Baseline in Serum Krebs von den Lungen-6 at Week 24
Ramy czasowe: Baseline, Week 12, and Week 24

Serum Krebs von den Lungen-6 (KL-6) concentration will be measured as a biomarker associated with interstitial lung disease activity and severity.

Baseline, Week 12, and Week 24
Change From Baseline in EULAR Sjögren's Syndrome Disease Activity Index at Week 24
Ramy czasowe: Baseline, Week 12, and Week 24

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) will be assessed at each specified visit. The outcome is Week 24 ESSDAI minus baseline ESSDAI.

Baseline, Week 12, and Week 24

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Changes in Peripheral B-cell Subsets and Related Biomarkers
Ramy czasowe: Baseline, Week 12, and Week 24

Changes from baseline in total B cells, B-cell subsets, immunoglobulins, and soluble CD25 will be evaluated. Associations between immunologic changes and changes in FVC% predicted, DLCO% predicted, Warrick score, and KL-6 will be explored.

Baseline, Week 12, and Week 24

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Główny śledczy: Yuan Jia, Peking University Institute of Rheuamotology and Immunology

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

1 maja 2026

Zakończenie podstawowe (Szacowany)

16 września 2027

Ukończenie studiów (Szacowany)

20 listopada 2027

Daty rejestracji na studia

Pierwszy przesłany

21 września 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

21 września 2026

Pierwszy wysłany (Rzeczywisty)

28 września 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

28 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

21 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • 2026-Telitacicept-SjD-ILD

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .